drugset
drugset / Trial / NCT03030183

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

NCT03030183 ↗

Phase 2 Completed 3 enrolled Ra Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to eculizumab. Patients will be treated with RA101495 for 12 weeks.

Timeline

Start
2017-04-17
Primary completion
2018-03-28
Completion
2018-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Zilucoplan Peptide 0.1 mg/kg Subcutaneous

Indications

paroxysmal nocturnal hemoglobinuria